Liraglutide (Victoza) Lowers Heart Risks in Diabetes Patients

International trial follows more than 9,000 patients for up to five years

Novo Nordisk has announced results from the LEADER trial, which investigated the cardiovascular safety of liraglutide (Victoza) during a period of up to five years in more than 9,000 adults with type-2 diabetes at high risk for major adverse cardiovascular events.

The LEADER trial was an international, randomized, double-blind, placebo-controlled study investigating the long-term effects of liraglutide (1.2 mg and 1.8 mg) compared with placebo, both in addition to standard of care, in patients with type-2 diabetes at high risk of cardiovascular events. The trial was initiated in September 2010 and followed 9,340 diabetes patients for three and a half to five years. The study’s primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

The trial met its primary endpoint, demonstrating noninferiority as well as superiority, with a statistically significant reduction in cardiovascular risk. The superior reduction of major adverse cardiovascular events demonstrated by liraglutide was derived from all three components of the endpoint. The safety profile of liraglutide in this study was generally consistent with that seen in previous liraglutide clinical trials.

Liraglutide is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence that is 97% similar to that of endogenous human GLP-1.It was approved by the FDA in 2010 as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes.

Detailed results of the new study are planned to be presented at the 76th Scientific Sessions of the American Diabetes Association in June 2016.

More Headlines

Drug treats hematologic malignancies
Task Force Issues Draft Recommendation Statement on Screening for Latent TB Infection in Adults
Experts find “moderate benefit” from screening high-risk individuals
FDA Clears First Test for Detection of Carbapenem Resistance Genes in “Superbugs”
Shipments begin later this month
Medicare to Test New Payment Approaches for Prescription Drugs
Current reimbursement encourages doctors to prescribe higher-priced medications
WHO Says Zika Vaccine Trials May Come Too Late
Experts identify top priorities
Docs Keep Overprescribing Addictive Drugs Despite Advisory Letter
Medicare communication has no effect on prescribing practices, authors find
International Consortium Selects ICON to Help Advance Value-Based Health Care
Company launches global health care outcomes benchmarking program
New Osteoporosis Treatments on the Horizon
National foundation issues report
Study: Retail Clinics Hike Health Care Costs
Savings offset by increased use of medical services